131674-39-0

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-chloropyridin-3-yl)ethanol is used as a building block for the synthesis of various pharmaceutical products due to its unique chloropyridinyl group, which allows for the creation of diverse chemical structures with potential therapeutic applications.
Used in Agrochemical Industry:
1-(2-chloropyridin-3-yl)ethanol is used as a building block for the synthesis of agrochemical products, contributing to the development of new compounds with pesticidal or herbicidal properties.
Used in Organic Synthesis:
1-(2-chloropyridin-3-yl)ethanol is used as a reagent in organic synthesis, enabling the formation of a wide range of chemical compounds through various reaction pathways.
Used in Pharmaceutical Research:
1-(2-chloropyridin-3-yl)ethanol is used as an intermediate in the production of active pharmaceutical ingredients, facilitating the development of new drugs with improved efficacy and safety profiles.
Used in Drug Development:
1-(2-chloropyridin-3-yl)ethanol is used in the study and development of new drug compounds, providing a foundation for the discovery of innovative therapeutic agents with potential applications in various medical fields.

Upstream product

• 109-09-1 2-chloropyridine 
• 75-07-0 acetaldehyde 
• 75-16-1 methylmagnesium bromide 
• 36404-88-3 2-chloro-3-carbaldehydepyridine 

Downstream Products

• 55676-21-6 3-acetyl-2-chloropyridine 
• 62838-65-7 1-(2-hydroxypyridin-3-yl)ethanone 
• 65326-33-2 1-(2-amino-3-pyridinyl)-1-ethanone 
• 131674-40-3 1-(2-methoxypyridin-3-yl)ethanone 
• 916325-84-3 methyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate 
• 916325-85-4 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid 
• 1314734-59-2 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde 
• 1314734-68-3 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde 
• 916325-83-2 pyrazolo[3,4-b]pyridine-3-carboxylic acid methyl ester 
• 116855-08-4 1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid 
• 877770-64-4 1-(2,4-dichlorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid methyl ester 
• 116834-96-9 3-methyl-1H-pyrazolo[3,4b]pyridine 

Relevant academic research and scientific papers

PRMT5 INHIBITORS

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF

Indazole macrocycle compounds of formula (I) for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. Formula (I)

3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.

LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT

Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject.

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

Provided herein are compounds according to Formula (I) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers.

Lonidamine analogues and their use in male contraception and cancer treatment

Novel compounds useful for inhibiting spermatogenesis and cancer treatment, and in particular as inhibitors of heat shock proteins and/or elongation factor 1 alpha.

Le phenyl-lithium: nouvel agent de metallation du cycle pyridinique

Nucleophilic addition was the sole reaction of phenyl-lithium with a pyridinic ring; now the novel catalysed metallation, with phenyl-lithium, of many substituted pyridine compounds giving various derivatives in high yields with many different reagents, has been achieved.

Improved Synthesis of 2,3-Disubstituted Pyridines by Metallation of 2-Chloropyridine: a Convenient Route to Fused Polyheterocycles

Chemoselective directed metallation of 2-chloropyridine allows the synthesis of 2-substituted 3-carbonylated pyridines, advantage being taken of the metallation ortho-directing effect of the halogen, as well as its reactivity towards nucleophiles.Thus (2-chloro-, 2-methoxy-, and 2-amino-3-pyridyl)-ethanones and -arylmethanones as well as carbaldehydes have been prepared.Some of these ortho-disubstituted intermediates have been readily cyclized to fused polyheterocycles such as naphthiridines and aza-analoges of coumarins, xanthones, and acridones.